Advisors Capital Management LLC Makes New $59.34 Million Investment in Bristol Myers Squibb Company $BMY

Key Points

• Advisors Capital Management purchased 1.03 million Bristol Myers Squibb shares worth approximately $59.34 million, giving it a 0.05% stake. Institutional investors collectively own 76.41% of BMY.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $66.06, although Jefferies downgraded the stock to “Hold.”
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share and revenue of $12.97 billion, exceeding estimates, while maintaining a quarterly dividend of $0.63 per share, or a 3.8% annualized yield.

Advisors Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,029,843 shares of the biopharmaceutical company's stock, valued at approximately $59,340,000. Advisors Capital Management LLC owned about 0.05% of Bristol Myers Squibb at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. MJP Associates Inc. ADV purchased a new position in Bristol Myers Squibb in the 2nd quarter worth $322,000. PCM Encore LLC purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $313,000. Vise Technologies Inc. purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $8,177,000. OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $1,559,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Bristol Myers Squibb in the second quarter worth about $742,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Raymond James Financial started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "strong-buy" rating for the company. Jefferies Financial Group cut Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Guggenheim reiterated a "buy" rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Argus raised Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. Finally, Citigroup restated a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Bristol Myers Squibb Trading Down 3.1%

BMY opened at $65.54 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business has a 50 day simple moving average of $60.35 and a two-hundred day simple moving average of $59.31. The firm has a market capitalization of $133.88 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source